TOBRADEX OPH OINT Rx
Generic Name and Formulations:
Tobramycin 0.3%, dexamethasone 0.1%; contains chlorobutanol.
Alcon Laboratories, Inc.
Indications for TOBRADEX OPH OINT:
Ocular inflammation associated with infection or risk thereof.
Adults and Children:
<2yrs: not recommended. ≥2yrs: apply small amount (½ inch) in conjunctival sac up to 3–4 times daily; max 8g for initial ℞.
Viral, fungal, or mycobacterial infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections, intraocular pressure and cataracts in prolonged use. Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Aminoglycoside + steroid.
Local effects (eg, eye pain, eyelids pruritus, eyelid edema, conjunctival hyperemia or erythema), increased intraocular pressure, glaucoma, cataracts, corneal perforations, optic nerve damage, delayed wound healing, secondary infection.
Susp—2.5mL, 5mL, 10mL; Oint—3.5g
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL